ACTIVE

Benebiose

Export PDF
Financial year 2025 · closed on 31/12/2025
Net result
-565,6 €
+96.3% YoY
Gross margin
231,4 €
+101.6% YoY
Equity
-8,2 k €
-7.4% YoY

What does Benebiose do?

Benebiose is a Private limited company incorporated in 2022. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent.

Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0784.521.548
Incorporation
05/04/2022
Legal form
Private limited company
Registered office
Technologiepark-Zwijnaarde 82 box 41
9052 Gent · FlandreSee on map
Contributed capital
230 000,00 €
Latest accounts
31/12/2025
Activities (NACE)
72101Research and experimental development on natural sciences and engineering· main72110Research and experimental development on biotechnology
View the BCE/KBO Public Search record →
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 4 financial years

2025202420232022
Income statement
Gross margin231,4 €-14,3 k €-133,3 k €-85,8 k €
EBITDA-178,0 €-14,9 k €-133,7 k €-86,2 k €
Operating result-178,0 €-14,9 k €-133,7 k €-86,2 k €
Net result-565,6 €-15,1 k €-135,0 k €-87,5 k €
Balance sheet
Equity-8,2 k €-7,7 k €7,5 k €112,5 k €
Total assets3,0 k €4,0 k €10,7 k €112,8 k €
Cash2,3 k €2,1 k €7,4 k €87,0 k €
Debts11,2 k €11,7 k €3,3 k €347,5 €
Governance

Board of directors

Seen on filing of 31/12/2025 · 4 active · 2 ended

Active mandates

Inbiose

Director · since 05 avril 2022 · until 12 mai 2027 · 0534.887.593

Represented by Joeri BEAUPREZ

Active
Richard PARK

Director · since 05 avril 2022 · until 12 mai 2027

Active
Soetaert

Director · since 05 avril 2022 · until 12 mai 2027 · 0835.699.639

Represented by Wim Soetaert

Active
Woo KANG SEUNG

Director · since 05 avril 2022 · until 12 mai 2027

Active

Ended mandates

Inbiose

Director · since 05 avril 2022 · until 12 mai 2027 · 0534.887.593

Represented by Joeri Beauprez

Ended
Seung Woo Kang

Director · since 05 avril 2022 · until 12 mai 2027

Ended
At this address

Other companies at this address

CompanyCBE no.
Amalus Therapeutics● Bankrupt
0803.929.268
APCOR R&M● Active
0600.952.909
Ardoyen● Active
0875.102.821
AVROXA● Active
0687.774.936
BioNeering● Active
0807.194.309
CONTREL EUROPE● Active
0426.204.637
CRODEON TECHNOLOGIES● Active
0642.754.761
Cryptobiotix● Active
0762.565.104
Gulliver Biomed● Active
0692.527.837
ImplicitMeasures.com● Bankrupt
0657.989.701
Inbiose● Active
0534.887.593
INCUBATIE- EN INNOVATIECENTRUM UNIVERSITEIT● Active
0440.054.752
INNOVATIVE PHARMACEUTICS● Active
0883.574.582
Inspect● Active
0645.950.417
INVIBES ADVERTISING● Active
0836.533.938
KYTOS● Active
0768.755.286
Lares Solutions● Active
1015.346.906
MAYAKU PHARMACEUTICAL DEVELOPMENT● Active
0755.350.975
Microbial Resource Management Health● Active
0742.910.132
Microbial Resource Management Technologies● Active
0667.765.816
Annual accounts

Full financial information

2025202420232022
Type of accountMicro modelMicro modelMicro modelMicro model
Start of the financial year01/01/202501/01/202401/01/202305/04/2022
Closing of the financial year31/12/202531/12/202431/12/202331/12/2022
Length of the financial year12 months12 months12 months9 months
Filing date10/07/202618/07/202514/05/202402/06/2023
General meeting12/06/202626/06/202508/05/202410/05/2023
Currency of the financial yearEUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

4 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Micro model31/12/202512/06/202610/07/2026DutchPDF
Micro model31/12/202426/06/202518/07/2025DutchPDF
Micro model31/12/202308/05/202414/05/2024DutchPDF
Micro model31/12/202210/05/202302/06/2023DutchPDF
Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 4 active · 2 ended

Active mandates

Inbiose

Director · since 05 avril 2022 · until 12 mai 2027 · 0534.887.593

Represented by Joeri BEAUPREZ

Active
Richard PARK

Director · since 05 avril 2022 · until 12 mai 2027

Active
Soetaert

Director · since 05 avril 2022 · until 12 mai 2027 · 0835.699.639

Represented by Wim Soetaert

Active
Woo KANG SEUNG

Director · since 05 avril 2022 · until 12 mai 2027

Active

Ended mandates

Inbiose

Director · since 05 avril 2022 · until 12 mai 2027 · 0534.887.593

Represented by Joeri Beauprez

Ended
Seung Woo Kang

Director · since 05 avril 2022 · until 12 mai 2027

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Other07/04/2022
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-565,6 €↑
  2. 2024
    Annual accounts 2024-15,1 k €↑
  3. 2023
    Annual accounts 2023-135,0 k €↓
  4. 2022
    Annual accounts 2022-87,5 k €
  5. 05/04/2022
    IncorporationPrivate limited company